Evidence map›Paper›PMID 42687481›Full record

ArticleJournal of liver cancer2026

Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.

Hae Lim Lee, Su Jong Yu, Sung Hak Lee, Min Woo Lee, Han Ah Lee, Yuri Cho, Jeong-Ju Yoo, Ha Il Kim, Jae Geun Lee, Hye Won Lee and 28 more

Abstract read
In one paragraph

Article in Journal of liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Hae Lim Lee *The Korean Liver Cancer Association, Seoul, Korea.
Su Jong Yu *The Korean Liver Cancer Association, Seoul, Korea.
Sung Hak LeeThe Korean Liver Cancer Association, Seoul, Korea.
Min Woo LeeThe Korean Liver Cancer Association, Seoul, Korea.
Han Ah LeeThe Korean Liver Cancer Association, Seoul, Korea.
Yuri ChoThe Korean Liver Cancer Association, Seoul, Korea.
Jeong-Ju YooThe Korean Liver Cancer Association, Seoul, Korea.
Ha Il KimThe Korean Liver Cancer Association, Seoul, Korea.
Jae Geun LeeThe Korean Liver Cancer Association, Seoul, Korea.
Hye Won LeeThe Korean Liver Cancer Association, Seoul, Korea.
Jihyun AnThe Korean Liver Cancer Association, Seoul, Korea.
Sun Young YimThe Korean Liver Cancer Association, Seoul, Korea.
Pil Soo SungThe Korean Liver Cancer Association, Seoul, Korea.
Jonggi ChoiThe Korean Liver Cancer Association, Seoul, Korea.
Jae Hyun YoonThe Korean Liver Cancer Association, Seoul, Korea.
Eun Ju ChoThe Korean Liver Cancer Association, Seoul, Korea.
Jinhong JungThe Korean Liver Cancer Association, Seoul, Korea.
Dongho HyunThe Korean Liver Cancer Association, Seoul, Korea.
Ijin JooThe Korean Liver Cancer Association, Seoul, Korea.
Yu Rim LeeThe Korean Liver Cancer Association, Seoul, Korea.
YoungRok ChoiThe Korean Liver Cancer Association, Seoul, Korea.
Bo Hyun KimThe Korean Liver Cancer Association, Seoul, Korea.
Sung Hyun KimThe Korean Liver Cancer Association, Seoul, Korea.
Soon Sun KimThe Korean Liver Cancer Association, Seoul, Korea.
Jeong-Han KimThe Korean Liver Cancer Association, Seoul, Korea.
Haeryoung KimThe Korean Liver Cancer Association, Seoul, Korea.
Pyoung-Jae ParkThe Korean Liver Cancer Association, Seoul, Korea.
Hyun Phil ShinThe Korean Liver Cancer Association, Seoul, Korea.
Ki Tae YoonThe Korean Liver Cancer Association, Seoul, Korea.
Sang Min YoonThe Korean Liver Cancer Association, Seoul, Korea.
Minjong LeeThe Korean Liver Cancer Association, Seoul, Korea.
Jai Young ChoThe Korean Liver Cancer Association, Seoul, Korea.
Jin-Young ChoiThe Korean Liver Cancer Association, Seoul, Korea.
Do Young KimThe Korean Liver Cancer Association, Seoul, Korea.
June Sung LeeThe Korean Liver Cancer Association, Seoul, Korea.
Mi-Sook KimThe Korean Liver Cancer Association, Seoul, Korea.
Kyung Sik KimThe Korean Liver Cancer Association, Seoul, Korea. kskim88@yuhs.ac.
26th Scientific Committee of the Korean Liver Cancer Association

Funding

Korean Liver Cancer Association KLCA-19-01
6 · The paper itself

Abstract

The role of liver biopsy in hepatocellular carcinoma (HCC) is being re-evaluated in the era of precision oncology and biomarker-driven systemic therapy. Although histopathological examination remains the diagnostic gold standard, HCC is unique among solid tumors in that accurate non-invasive imaging criteria allow diagnosis without routine biopsy in selected clinical settings. However, increasing biological heterogeneity, expanding therapeutic options, and the growing need for molecular stratification have renewed interest in tissue-based evaluation. Recent international guidelines have gradually broadened the indications for liver biopsy, particularly in selected diagnostic scenarios, prior to systemic therapy, and for molecular profiling. Beyond diagnostic confirmation, liver biopsy provides important information for histological subtyping, prognostic stratification, and biomarker discovery. Advances in immunohistochemistry, next-generation sequencing, and artificial intelligence-assisted pathology have further enhanced the clinical value of tumor tissue. In parallel, contemporary cohort studies indicate that liver biopsy is associated with low complication rates when modern techniques and standardized peri-procedural management are applied. Despite these advances, the integration of liver biopsy into routine clinical practice remains limited. To contextualize this gap, the Korean Liver Cancer Association conducted a nationwide survey of HCC specialists. The survey showed that liver biopsy is infrequently performed in current practice due to perceived procedural risks and limited immediate impact on therapeutic decision-making. Taken together, accumulating evidence supports a reappraisal of the clinical role of liver biopsy in HCC. Optimizing procedural safety, standardizing indications, and integrating tissue-based molecular insights into therapeutic decision-making may help bridge the gap between emerging evidence and real-world practice.

Indexed as

Biomarkers, tumorBiopsyCarcinoma, hepatocellularMolecular targeted therapyPrecision medicine

Identifiers

PMID42687481
PMCPMC13669495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.